AI + MedicineAI now helps find drug targets, predict protein shapes and design molecules. But most drugs fail in clinical trials because they don't work well enough or are too toxic, and AI hasn't yet shown it can change that.
Companies + StocksMany biotech startups spend years building evidence rather than selling products. This map traces the stations most pass through, from licensing a discovery to the forks where companies partner, sell, go public or stop.
DeepTech + MedTechFrom over-the-counter glucose monitors to AI-enabled imaging software, medical devices are getting smaller, smarter and more autonomous. Here is what is authorized, what is still experimental, and what could slow things down.
DeepTech + MedTechNo bioprinted solid organ has been transplanted into a person, but bioprinting has produced striking lab and animal results. Here is what works today, what has reached early human testing, and what still stands in the way.
DeepTech + MedTechOrganoids and organ-on-a-chip systems let researchers test drugs on human tissue models before people. The early evidence is promising but specific, and the models still miss much of real human biology.
Companies + StocksMost medical products begin as university research, then pass through tech transfer offices, licences or spinouts, and the regulatory system. This guide maps each step and the reasons discoveries stall.
AI + MedicinePersonalized computer models of the heart and in-silico trials are already used in research and regulation. Scaling them into a living digital twin for every patient raises hard questions of biology, validation and trust.